StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$6.76+0.01 (+0.15%)

Close on Nov 20, 2026Market cap $362.54MP/E –Yield –

Avalo Therapeutics shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Avalo Therapeutics's shares outstanding was 44M at Jun 30, 2026. For fiscal 2025 it was 13M, up 78.8% from the year before. The highest annual figure on record is 13M in fiscal 2025.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 202513M+78.8%
FY2024Dec 31, 20247M+2599.2%
FY2023Dec 31, 20230M+608.5%
FY2022Dec 31, 20220M+224.7%
FY2018Dec 31, 20180M+85.4%
FY2017Dec 31, 20170M+112.4%
FY2016Dec 31, 20160M+296.6%
FY2015Dec 31, 20150M+246.6%
FY2014Dec 31, 20140M+1.4%
FY2013Dec 31, 20130M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 202644M+302.6%
Q1 FY2026Mar 31, 202620M+91.2%
Q4 FY2025Dec 31, 202518M+75.9%
Q3 FY2025Sep 30, 202514M+29.8%
Q2 FY2025Jun 30, 202511M+41.5%
Q1 FY2025Mar 31, 202511M+1123.5%
Q4 FY2024Dec 31, 202410M+5218.3%
Q3 FY2024Sep 30, 202411M+18423.9%
Q2 FY2024Jun 30, 20248M+15568.5%
Q1 FY2024Mar 31, 20241M+2089.5%
Q3 FY2023Sep 30, 20230M+396.8%
Q2 FY2023Jun 30, 20230M+48.6%
Q1 FY2023Mar 31, 20230M+24.7%
Q4 FY2022Dec 31, 20220M+176.7%
Q3 FY2022Sep 30, 20220M+226.0%
Q2 FY2022Jun 30, 20220M+249.9%
Q1 FY2022Mar 31, 20220M+260.2%
Q4 FY2018Dec 31, 20180M+35.5%
Q3 FY2018Sep 30, 20180M+61.9%
Q2 FY2018Jun 30, 20180M+143.1%
Q1 FY2018Mar 31, 20180M+206.6%
Q4 FY2017Dec 31, 20170M+225.4%
Q3 FY2017Sep 30, 20170M+144.5%
Q2 FY2017Jun 30, 20170M–
Q1 FY2017Mar 31, 20170M–
Q4 FY2016Dec 31, 20160M–
Q3 FY2016Sep 30, 20160M–

More Avalo Therapeutics figures

See a number that looks wrong?